Memory Pharmaceuticals Earns Milestone Payment For Phase 2a Trial Of MEM 1003 In Bipolar Disorder 
Memory Pharmaceuticals Corp. (Nasdaq: MEMY) today announced that it had earned a milestone payment of $960,000 from the Stanley Medical Research Institute (SMRI) related to the ongoing Phase 2a trial of MEM 1003 in patients with acute mania in bipolar disorder. [click link for full article]